Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexisting Systemic Autoimmune Rheumatic Diseases
Methodological detailssystematic literature review, GRADE approach, multidisciplinary panel
- Systematic literature review
- GRADE approach
- Multidisciplinary panel
Recommendations
As issued by the authors
- Best practice statements (8)
Shared decision making between patients and their care team and careful consideration of risk of SARD flare, risk of organ- or life-threatening manifestations, and potential effect of immunosuppression on cancer outcomes
Seven specific recommendations, 1 each for preexisting SLE, SSc, Sjögren disease, myositis, sarcoidosis, vasculitis and Behçet disease, considering both available evidence and expert consensus
General recommendation for preexisting systemic autoimmune rheumatic diseases (SARDs): continue baseline immunosuppression, particularly if there are organ- or life-threatening manifestations
Original publication
Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexisting Systemic Autoimmune Rheumatic Diseases. J Rheumatol. Published 15 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →